Immunosuppressant Peptide Abu-TGIRIS-Abu-NH2 and its Application for Treatment of Multiple Sclerosis

V. I. Turobov, В. Н. Азев, А. Б. Шевелев, Natalia V. Pozdniakova, Yulia K. Biryukova, А. Н. Мурашев, Valery M. Lipkin, Igor P. UdovichenkoBioNanoScience 2018 · DOI

Abstract

Immunosuppressant peptide immunocortin for the first time was described in 1993. It corresponds to residues 11-20 of human Ig heavy chain (conserved motif of V<sub>H</sub> domain). There are no data about production of immunocortin by proteolysis of Ig in vivo. Synthetic immunocortin in concentration ~ 10<sup>-9</sup> M suppresses phagocytosis in peritoneal macrophages, ConA-dependent blast transformation of rat lymphocytes, exhibits ACTH-like neurotropic activity and was suggested as a potential drug for treatment of a multiple sclerosis (MS). Here, we report a sequence and method of synthesis of Abu-TGIRIS-Abu-NH<sub>2</sub> (Abu, alpha-aminobutyric acid), an artificial analogue of immunocortin. Biological trials of peritoneally injected Abu-TGIRIS-Abu-NH<sub>2</sub> gave an evidence of its better efficacy versus immunocortin in a test for suppression of the experimental autoimmune encephalomyelitis (EAE) in Dark Agouti (DA) rats.

Introduction

Multiple Sclerosis (MS) is a chronic autoimmune disorder where the immune system attacks the myelin sheath of nerve fibers in the central nervous system. While various therapies exist, many are prohibitively expensive or ineffective against progressive forms of the disease. This study focuses on "immunocortin," a fragment of the human immunoglobulin (Ig) heavy chain known for its ACTH-like immunosuppressive properties. However, natural immunocortin is unstable in vivo, limiting its clinical utility. Researchers have developed Abu-TGIRIS-Abu-NH$_2$, a synthetic analogue designed to retain therapeutic benefits while improving stability and potency.

Methodology

The research utilized a combination of rational computational design, optimized chemical synthesis, and in vivo biological trials.

Rational Design and Synthesis

Starting with the prototype Abu-SSVKVS-Abu-NH$_2$, the team performed amino acid substitutions based on structural similarity and local environment analysis to create Abu-TGIRIS-Abu-NH$_2$. Synthesis was performed via Solid-Phase Peptide Synthesis (SPPS) using Fmoc/tBu chemistry. A significant challenge was identified in the "slow acylation" of Arginine (Arg) when reacting with Isoleucine (Ile) due to steric hindrance. This was resolved by using a highly reactive fluoro-anhydride derivative (Fmoc-Ile-F), which achieved near-complete conversion (>98%).

Comparison of yield and purity for different SPPS methodologies.

Animal Modeling

The peptide was tested on 30 Dark Agouti (DA) rats with induced Experimental Autoimmune Encephalomyelitis (EAE), a standard proxy for human MS. Rats were divided into three groups: Control, Prototype peptide, and the new Abu-TGIRIS-Abu-NH$_2$ peptide, administered intraperitoneally at 400 μg/kg.

Results and Discussion

The optimized Fmoc/tBu methodology yielded the new peptide at 12.2%, a significant improvement over the 7.1% yield of the older Boc/Bzl method used for the prototype. High-Performance Liquid Chromatography (HPLC) verified a final purity exceeding 97%.

Biological Efficacy

In the EAE rat model, the prototype peptide merely delayed the onset of the acute phase of paralysis. In contrast, the new peptide, Abu-TGIRIS-Abu-NH$_2$, effectively abolished the most severe neurological symptoms.

EAE clinical scores over time for control and peptide-treated groups.

The peptide mimics the neurotropic activity of Adrenocorticotropic Hormone (ACTH) but is significantly smaller, potentially avoiding the severe systemic side effects associated with full-scale hormone therapy. Furthermore, its likely low penetration of the blood-brain barrier may reduce central nervous system side effects.

Conclusion

Abu-TGIRIS-Abu-NH$_2$ represents a promising therapeutic candidate for Multiple Sclerosis, demonstrating superior efficacy and improved synthesis yields over previous prototypes. While the current yield of ~12% presents a challenge for industrial scaling, the peptide's ability to suppress severe EAE symptoms warrants extensive toxicological trials and further investigation into its molecular mechanism of action.

Summary updated

Abstract

Immunosuppressant peptide immunocortin for the first time was described in 1993. It corresponds to residues 11-20 of human Ig heavy chain (conserved motif of V<sub>H</sub> domain). There are no data about production of immunocortin by proteolysis of Ig in vivo. Synthetic immunocortin in concentration ~ 10<sup>-9</sup> M suppresses phagocytosis in peritoneal macrophages, ConA-dependent blast transformation of rat lymphocytes, exhibits ACTH-like neurotropic activity and was suggested as a potential drug for treatment of a multiple sclerosis (MS). Here, we report a sequence and method of synthesis of Abu-TGIRIS-Abu-NH<sub>2</sub> (Abu, alpha-aminobutyric acid), an artificial analogue of immunocortin. Biological trials of peritoneally injected Abu-TGIRIS-Abu-NH<sub>2</sub> gave an evidence of its better efficacy versus immunocortin in a test for suppression of the experimental autoimmune encephalomyelitis (EAE) in Dark Agouti (DA) rats.
BibTeX
@inproceedings{turobov2018immunosuppressant,
  author = {V. I. Turobov and В. Н. Азев and А. Б. Шевелев and Natalia V. Pozdniakova and Yulia K. Biryukova and А. Н. Мурашев and Valery M. Lipkin and Igor P. Udovichenko},
  title = {{Immunosuppressant Peptide Abu-TGIRIS-Abu-NH2 and its Application for Treatment of Multiple Sclerosis}},
  booktitle = {BioNanoScience},
  year = {2018},
  doi = {10.1007/s12668-018-0513-8},
}
Figure